| 1 |
34826601 | The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. | 2022 Jan |
5 |
| 2 |
34855271 | LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. | 2022 Feb |
4 |
| 3 |
35447433 | Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment. | 2022 Jul 5 |
1 |
| 4 |
33028591 | Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. | 2021 Jan 1 |
1 |
| 5 |
33986687 | SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. | 2021 |
1 |
| 6 |
33993094 | Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. | 2021 Aug |
1 |
| 7 |
34087353 | Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. | 2021 Aug |
7 |
| 8 |
34145930 | Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. | 2021 Sep |
2 |
| 9 |
34298655 | Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. | 2021 Jul 9 |
1 |
| 10 |
34439260 | The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells. | 2021 Aug 15 |
2 |
| 11 |
34464874 | A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine. | 2021 Dec 5 |
2 |
| 12 |
34491761 | Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance. | 2021 Sep 23 |
2 |
| 13 |
31678994 | Betacellulin drives therapy resistance in glioblastoma. | 2020 Apr 15 |
1 |
| 14 |
31821539 | ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. | 2020 Mar 15 |
2 |
| 15 |
31999837 | Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). | 2020 Jan 1 |
2 |
| 16 |
32354888 | Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice. | 2020 May-Jun |
2 |
| 17 |
32497272 | MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. | 2020 Aug 15 |
1 |
| 18 |
32510788 | Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. | 2020 Aug 17 |
2 |
| 19 |
32631532 | Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. | 2020 Aug 15 |
1 |
| 20 |
32659740 | Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival. | 2020 Oct |
1 |
| 21 |
32873635 | Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway. | 2020 Nov 1 |
2 |
| 22 |
33049499 | Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. | 2020 Dec |
8 |
| 23 |
33064977 | LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway. | 2020 Nov |
5 |
| 24 |
30642543 | Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. | 2019 Jan |
1 |
| 25 |
30807997 | Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. | 2019 Apr |
2 |
| 26 |
31108249 | Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. | 2019 Sep |
2 |
| 27 |
31254668 | A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. | 2019 Nov |
4 |
| 28 |
31314158 | Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. | 2019 Oct |
1 |
| 29 |
31563735 | Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. | 2019 Nov |
1 |
| 30 |
31791326 | Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. | 2019 Dec 2 |
2 |
| 31 |
27439477 | Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104. | 2016 Oct |
1 |